A. Yarikov, A. Ermolaev, A. Fraerman, P. Smirnov, A. Logutov, S. Tsybusov
{"title":"Management of a Patient With Multiple Traumatic Intracranial Hematomas in a Neurosurgical Clinic: Literature Review and Clinical Case","authors":"A. Yarikov, A. Ermolaev, A. Fraerman, P. Smirnov, A. Logutov, S. Tsybusov","doi":"10.33619/2414-2948/95/12","DOIUrl":null,"url":null,"abstract":"Multiple traumatic intracranial hematomas are one of the types of severe TBI, which are distinguished by high mortality and lead to disability. The article describes in detail the pathogenesis of TBI, the features of the clinical picture, outlines the basic principles of treatment and provides clinical examples of complex treatment of multiple intracranial hematomas. Timely treatment of secondary damage mechanisms in TBI will lead to a significant reduction in mortality and severe disabling consequences. Drug therapy is represented by a number of groups of drugs: calcium channel blockers, antioxidants and antihypoxants, NMDA receptor antagonists, inflammatory and immune response blockers, cell membrane stabilizers that improve synaptic transmission, apoptosis blockers, drugs with neuron-specific neurotrophic action, immunosuppressors, inhibitors of the renin-angiotensin-aldosterone system.","PeriodicalId":471421,"journal":{"name":"Бюллетень науки и практики","volume":"38 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Бюллетень науки и практики","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33619/2414-2948/95/12","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Multiple traumatic intracranial hematomas are one of the types of severe TBI, which are distinguished by high mortality and lead to disability. The article describes in detail the pathogenesis of TBI, the features of the clinical picture, outlines the basic principles of treatment and provides clinical examples of complex treatment of multiple intracranial hematomas. Timely treatment of secondary damage mechanisms in TBI will lead to a significant reduction in mortality and severe disabling consequences. Drug therapy is represented by a number of groups of drugs: calcium channel blockers, antioxidants and antihypoxants, NMDA receptor antagonists, inflammatory and immune response blockers, cell membrane stabilizers that improve synaptic transmission, apoptosis blockers, drugs with neuron-specific neurotrophic action, immunosuppressors, inhibitors of the renin-angiotensin-aldosterone system.